Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 12/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.52 |
| ▸ | CTSD | P07339 | 2/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
| ▸ | FNTB | P49356 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29590503 | 0.95 | BACE1 (0.58) | BACE1BACE2CTSD | |
| SCHEMBL29496478 | 0.91 | MMP2 (0.54) | SMN1; SMN2BACE1BACE2CTSD | |
| SCHEMBL29496483 | 0.91 | MMP2 (0.54) | SMN1; SMN2BACE1BACE2CTSD | |
| SCHEMBL29904560 | 0.91 | MMP2 (0.54) | SMN1; SMN2BACE1BACE2CTSD | |
| SCHEMBL30974493 | 0.91 | BACE1 (0.54) | SMN1; SMN2BACE1BACE2CTSDFNTA | |
| SCHEMBL10379927 | 0.90 | GNPAT (0.54) | SMN1; SMN2BACE1BACE2CTSDFNTA | |
| SCHEMBL10379929 | 0.90 | GNPAT (0.54) | SMN1; SMN2BACE1BACE2CTSDFNTA | |
| SCHEMBL30578962 | 0.89 | ERAP2 (0.56) | SMN1; SMN2BACE1BACE2CTSDFNTA | |
| SCHEMBL29590849 | 0.88 | BACE1 (0.64) | BACE1BACE2CTSD | |
| SCHEMBL30336809 | 0.88 | BACE1 (0.54) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | SMN1; SMN2 676/4885BACE1 530/4885BACE2 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.